Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AEZS-108 versus doxorubicin as second-line therapy for advanced or recurrent endometrial cancer
NL-OMON40258Phase 3Active, not recruiting
- Sponsor
- COSCIENS Biopharma Inc.
- Start
- May 2014
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in endometrial cancer (EC) comparing AEZS-108 with Doxorubicin (2 arms). Primary endpoint: Overall survival. Started May 2014; status: active, not recruiting.
02
Drugs
zoptarelin doxorubicindoxorubicin
03
Conditions
endometrial cancer (EC)
Beyond the preview
Go deeper on NL-OMON40258.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON40258.